Leonard Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Vice Chairman Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic Cleveland, OH
What adverse effects should clinicians be aware of when treating RA patients with IL-6 inhibitors?
What adverse effects should clinicians be aware of when treating RA patients with IL-6 inhibitors?
What is the precise immunopathobiologic mechanism of action (MoA) for agents targeting IL-6 in the setting of RA? How does IL-6 affect bone loss in RA?
Are IL-6 inhibitors synergistic with methotrexate and how do they compare to TNFIs as far as their efficacy as monotherapy in patients with RA?
What are the potential inflammatory interfaces that are affected by inhibition of the IL-6 cytokine pathway? How does each pathway potentially affect clinical manifestations of RA?
What are the unmet biomarker and/or therapeutic needs in patients with RA?
What are the unmet biomarker and/or therapeutic needs in patients with RA?
What is the current status of B-cell targeting agents?
What is the evidence for early, aggressive therapy with biologics in RA?
What is the evidence for early, aggressive therapy with biologics in RA?
What biomarkers and clinical findings are most useful for guiding therapy in RA?
What biomarkers and clinical findings are most useful for guiding therapy in RA?
What do current ACR guidelines recommend as far as sequencing therapy in patients who have had an insufficient response to methotrexate?